This is a copy of a story from 2000. However; The more people I speak with with RA have never heard of this vaccine. I felt comppelled to list this story again on my blog to imform anyone who may never have heard of theis vaccine.. This is a huge becon of light for all.
Corixa Receives U.S. Patent On AnervaX.RA Vaccine for the Treatment of Rheumatoid Arthritis
SEATTLE--(BW HealthWire)--April 11, 2000
Corixa Corporation (Nasdaq:CRXA), a research- and development-based biotechnology company, today announced that the United States Patent and Trademark Office (USPTO) has issued the Company a patent covering its AnervaX.RA(TM) rheumatoid arthritis (RA) vaccine.
Rheumatoid arthritis is a crippling disease, affecting an estimated 2.5 million Americans and a similar number of people worldwide. The patent, U.S. Patent Number 6,045,796, entitled "Vaccination with Peptide of MHC Class II Molecules for Treatment of Autoimmune Disease," includes claims covering the composition of the AnervaX.RA vaccine, as well as use of the vaccine to treat rheumatoid arthritis.
"This patent issuance represents continued advancement of our autoimmune disease efforts, building on our acquisition of Anergen in February 1999," said Steven Gillis, Ph.D., chairman and chief executive officer of Corixa. "The continued clinical development of our AnervaX.RA vaccine and the subsequent issuance of patents for the potential vaccine are important steps toward commercialization of this novel approach to the treatment of arthritis."
About Corixa's AnervaX.RA Vaccine
AnervaX.RA vaccine is a synthetic 20-amino acid peptide sequence (amino acids 57-76) from the Beta chain of the specific MHC class II molecules genetically linked to RA, and includes a "shared epitope," that is common to approximately 90 percent of RA patients. In autoimmune diseases like rheumatoid arthritis, the body erroneously recognizes components of cells or tissues as foreign antigens. These autoantigens are presented to the immune system by disease-linked MHC class II molecules on the surface of antigen-presenting cells (APC). The vaccine is designed to act as a therapeutic vaccine stimulating the production of a neutralizing immune response that prevents the autoimmune disease cascade by specifically blocking the presentation of self-antigen by disease-linked MHC molecules to autoreactive T cells that cause rheumatoid arthritis, potentially halting the progression of the disease. In a Phase I/II study, the vaccine provided sustained clinical benefit for up to twelve weeks after the last injection in a substantial proportion of patients with long-standing active RA, and had a low frequency of side effects. The peptide vaccine is one application of the AnervaX(TM) technology platform. Other applications include a peptide vaccine for the treatment of Type I diabetes, which is in pre-clinical development.
Corixa is a research- and development-based biotechnology company committed to treating and preventing autoimmune diseases, cancer and infectious diseases by understanding and directing the immune system. Corixa is focused on immunotherapeutic products and has a broad technology platform enabling both fully integrated vaccine design and the use of its separate, proprietary vaccine components on a standalone basis. The company partners with numerous developers and marketers of pharmaceuticals and diagnostic products with the goal of making its potential products, Powered by Corixa(TM), available to patients around the world. Corixa was founded in 1994 and is headquartered in Seattle, Wash., with additional operations in Hamilton, Mont. and Redwood City, Calif. For more information, please visit Corixa's website at www.corixa.com or call the company's investor relations information line at 877/4CORIXA or 877/426-7492.
Forward Looking Statements
Except for the historical information presented, the matters discussed in this press release are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Such risks and uncertainties include the failure of the AnervaX.RA vaccine to progress in clinical trials, adverse patient responses to the vaccine or the failure to prove safe or efficacious in the event of further clinical trials, and other risks detailed from time to time in the Corixa's public disclosure filings with the U.S. Securities and Exchange Commission (SEC), including the Annual Report on Form 10-K for the fiscal year ended December 31, 1999, and the Company's Registration Statement on Form S-3/A, filed on April 7, 2000. Copies of Corixa's public disclosure filings with the Securities and Exchange Commission (SEC) are available from its investor relations department.
COPYRIGHT 2000 Business Wire
COPYRIGHT 2008 Gale, Cengage Learning